1-4 of 4
Francois-Xavier Claret
Close
Sort by
Journal Articles

NPM-ALK Promotes Cell Cycle Progression through Activation of JNK and c-Jun in Anaplastic Large Cell Lymphoma.

Vasiliki Leventaki, MD, Elias Drakos, MD, Megan Lim, MD, Kojo S. Elenitoba-Johnson, MD, Francois-Xavier Claret, PhD, L. Jeffrey Medeiros, MD, George Z. Rassidakis, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 2057.
https://doi.org/10.1182/blood.V108.11.2057.2057
Published: 2006
Journal Articles

cJun Is Phosphorylated at Ser73 and Contributes to Cell Cycle Progression in Anaplastic Large Cell Lymphoma.

Vassiliki Leventaki, MD, Elias Drakos, MD, Francois-Xavier Claret, PhD, L. Jeffrey Medeiros, MD, George Z. Rassidakis, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2620.
https://doi.org/10.1182/blood.V106.11.2620.2620
Published: 2005
Journal Articles

Activation of mTOR Signaling Pathway Contributes to Tumoral Cell Survival in ALK-Positive Anaplastic Large Cell Lymphoma.

Francisco Vega, MD, PhD, L. Jeffrey Medeiros, MD, Coralyn Atwell, BS, Jeong Hee Cho, MD, PhD, Ling Tian, PhD, Francois-Xavier Claret, PhD, George Z. Rassidakis, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2419.
https://doi.org/10.1182/blood.V106.11.2419.2419
Published: 2005
Journal Articles

Inhibition of Akt increases p27 Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma

Brief Report
George Z. Rassidakis, Marianna Feretzaki, Coralyn Atwell, Ioannis Grammatikakis, Quan Lin, Raymond Lai, Francois-Xavier Claret, L. Jeffrey Medeiros, Hesham M. Amin
Journal: Blood
Blood (2005) 105 (2): 827–829.
https://doi.org/10.1182/blood-2004-06-2125
Published: 2005